Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.
Rhythm Biosciences has signed a multi-year commercial supply agreement with US-based Quansys Biosciences to manufacture ColoSTAT® consumable reagent kits at commercial scale. The deal formalises a two-year collaboration and secures ISO13485-certified, quality-assured production capacity, flexible scaling with demand, and established global logistics, underpinning the ColoSTAT® Access Program and future commercial rollout. By locking in reliable supply, scalable infrastructure and initial fixed pricing for cost predictability, the agreement marks a significant operational milestone that reduces manufacturing and quality risk and strengthens Rhythm’s readiness for broader market entry in colorectal cancer diagnostics.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian-based predictive cancer diagnostics company focused on developing and commercialising ColoSTAT®, a blood-based colorectal cancer test. Operating within the molecular science and biotechnology sector, the company targets global markets for early cancer detection through accessible, scalable diagnostic solutions.
Average Trading Volume: 609,773
Technical Sentiment Signal: Buy
Current Market Cap: A$48.9M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.